Business Context and Reporting Period
Company: Galectin Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 28, 2019
Reporting Period: Single event date (May 28, 2019)
Business Context: The registrant is a Nevada corporation with its principal executive office in Norcross, GA. Its common stock trades on The Nasdaq Capital Market under the symbol "GALT". This filing serves to disseminate a press release issued on the date of the report.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a notification of a press release and does not contain audited financial statements or quarterly results.
Material Changes
No material changes to financial position or operations are detailed within the text of this filing. The document solely references the issuance of a press release (Exhibit 99.1) without summarizing its content.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details regarding contingencies. The content is limited to the administrative disclosure of the press release attachment.
Investor Verification Checklist
- Review Exhibit 99.1 (the attached press release) to understand the specific event or announcement triggering this filing.
- Verify the company's current stock price and trading volume on The Nasdaq Capital Market under symbol GALT.
- Check subsequent filings (e.g., 10-Q or 10-K) for the most recent financial data, as this 8-K contains no financial metrics.
- Confirm the identity of the signatory, Jack W. Callicutt, as the Chief Financial Officer.